Gabexate mesilate, a synthetic protease inhibitor, reduces ischemia/reperfusion injury of rat liver by inhibiting leukocyte activation

Critical Care Medicine

Volumn 27, Issue 9, 1999, Pages 1958-1964

  Harada, Naoaki ^a   Okajima, Kenji ^a,b   Kushimoto, Shigeki ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b University School of Medicine   (Japan)

Author keywords

Gabexate mesilate; Ischemia reperfusion injury; Leukocytes; Liver injury; Rat interleukin 8; Synthetic protease inhibitors; Tumor necrosis factor

Indexed keywords

BLOOD CLOTTING FACTOR 10A; GABEXATE MESILATE; INTERLEUKIN 8; MYELOPEROXIDASE; PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE FLOW; BLOOD CLOTTING; CONTROLLED STUDY; DRUG MECHANISM; LEUKOCYTE ACTIVATION; LIVER DYSFUNCTION; LIVER INJURY; LIVER ISCHEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY;

ANALYSIS OF VARIANCE; ANIMALS; GABEXATE; INTERLEUKIN-8; LEUKOCYTES; LIVER; LIVER CIRCULATION; LIVER FUNCTION TESTS; MALE; NEUTROPHILS; PROSPECTIVE STUDIES; RANDOM ALLOCATION; RATS; RATS, WISTAR; REPERFUSION INJURY; SERINE PROTEINASE INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032884054     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199909000-00040     Document Type: Article

References (37)

1. 1. Atalla SL, Toledo-Pereyra H, MacKenzie GH, et al: Influence of oxygen-derived free radical scavengers on ischemic livers. Transplantation 1985; 40:584-590
2. 2. Hasselgren PO: Prevention and treatment of ischemia of the liver. Surg Gynecol Obstet 1987; 164:187-196
3. 3. Keller GA, West MA, Cerra FB, et al: Macrophage-mediated modulation of hepatic function in multi-system failure. J Surg Res 1985; 39:555-563
4. 4. Campbell EJ, Senior RM, McDonald JA, et al: Proteolysis by neutrophils: Reactive importance of cell-substrate contact and oxidative inactivation of protein inhibitors in vitro. J Clin Invest 1982; 70:845-852
5. 5. Carlos TM, Harlan JM: Leukocyte-endothelial adhesion molecules. Blood 1994; 84: 2068-2101
6. 6. Jaeschke H, Farhood A, Smith CW: Neutrophils contribute to ischemia/reperfusion injury in rat liver in vivo. FASEB J 1990; 4:3355-3359
7. 7. Vollmar B, Glasz J, Menger MD, et al: Leukocytes contribute to hepatic ischemia/ reperfusion injury via intercellular adhesion molecule-1-mediated venular adherence. Surgery 1995; 117:195-200
8. 8. Farhood A, McGuire GM, Manning AM, et al: Intercellular adhesion molecule 1 (ICAM-1) expression and its role in neutrophil-induced ischemia-reperfusion injury in rat liver. J Leukocyte Biol 1995; 57:368-374
9. 9. Kushimoto S, Okajima K, Uchiba M, et al: Role of granulocyte elastase in ischemia/ reperfusion injury of rat liver. Crit Care Med 1996; 24:1908-1912
10. 10. Klebanoff SJ, Vadas MA, Harlan JM, et al: Stimulation of neutrophils by tumor necrosis factor. J Immunol 1986; 136:4220-4225
11. 11. Paques E-P, Romisch J: Comparative study on the in vitro effectiveness of antithrombotic agents. Thromb Res 1991; 64:11-21
12. 12. Messori A, Rampazzo R, Scroccaro G, et al: Effectiveness of gabexate mesilate in acute pancreatitis. Dig Dis Sci 1995; 40:734-738
13. 13. Taenaka N, Shimada Y, Hirata T, et al: Gabexate mesilate (FOY) therapy of disseminated intravascular coagulation due to sepsis. Crit Care Med 1983; 9:735-738
14. 14. Murakami K, Okajima K, Uchiba M, et al: Gabexate mesilate, a synthetic protease inhibitor, attenuates endotoxin-induced pulmonary vascular injury by inhibiting tumor necrosis factor production by monocytes. Crit Care Med 1996; 24:1047-1053
15. 15. Taoka Y, Okajima K, Uchiba M, et al: Gabexate mesilate, a synthetic protease inhibitor, prevents compression-induced spinal cord injury by inhibiting activation of leukocytes in rats. Crit Care Med 1997; 25:874-879
16. 2 treatment. J Surg Res 1986; 40:167-175
17. 17. Lee SM, Clemens MG: Effect of α-tocopherol on hepatic mixed function oxidases in hepatic ischemia/reperfusion. Hepatology 1992; 15:276-281
18. 18. Bowers BA, Branum GD, Rotolo FS, et al: Bile flow. An index of ischemic injury. J Surg Res 1987; 42:565-569
19. 19. Clauss A: Rapid physiological coagulation method for the determination of fibrinogen. Acta Haematol 1957; 17:237-246
20. 20. Puchtler H, Waldrop FS, Meloan SN: On the mechanism of Mallory's phosphotungstic acid-haematoxylin stain. J Microsc 1980; 119: 383-390
21. 21. Shito M, Wakabayashi G, Ueda M, et al: Interleukin 1 receptor blockade reduces tumor necrosis factor production, tissue injury, and mortality after hepatic ischemia-reperfusion in the rat. Transplantation 1997; 63:143-148
22. 22. Watanabe K, Konishi K, Fujioka M, et al: The neutrophil chemoattractant produced by the rat kidney epithelioid cell line NRK-52E is a protein related to the KV/gro protein. J Biol Chem 1989; 264:19559-19563
23. 23. Yamasaki Y, Matsuo Y, Zagorski J, et al: New therapeutic possibility of blocking cytokine-induced neutrophil chemoattractant on transient ischemic brain damage in rats. Brain Res 1997; 759:103-111
24. 24. Clark BD, Bedrosian I, Schindler R, et al: Detection of interleukin 1α and β in rabbit tissues during endotoxemia using sensitive radioimmunoassays. J Appl Physiol 1991; 71: 2412-2418
25. 25. Yamaguchi Y, Hasama N, Okajima K, et al: Pretreatment with activated protein C or active human urinary thrombomodulin attenuates the production of cytokine-induced neutrophil chemoattractant following ischemia/reperfusion in rat liver. Hepatology 1997; 25:1136-1140
26. 26. Rawson RA: The binding of T-1824 and structurally related diazo dyes by the plasma proteins. Am J Physiol 1943; 138:708-717
27. 27. Bajaj SP, Rapaport SI, Prodanos CA: A simplified procedure for purification of human prothrombin, factor IX and factor X. Prep Biochem 1981; 11:397-412
28. 28. Morita T, Jackson CM: Localization of the structural difference between bovine blood coagulation factor XI and XII to tyrosine 18 in the activation peptide. J Biol Chem 1986; 261:4008-4014
29. 29. Taylor FB Jr, Chang AK, Peer GT, et al: DEGR-Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage. Blood 1991; 78:364-368
30. 30. Hisama N, Yamaguchi Y, Okajima K, et al: Anticoagulant pretreatment attenuates production of cytokine-induced neutrophil chemoattractant following ischemia-reperfusion of rat liver. Dig Dis Sci 1996; 41:1481-1486
31. 31. Colleti LM, Burtch GD, Remick DG, et al: The production of tumor necrosis factor alpha and the development of a pulmonary capillary injury following hepatic ischemia/ reperfusion. Transplantation 1990; 49: 268-272
32. 32. Komatsu H, Koo A, Ghadishah E, et al: Neutrophil accumulation in ischemic reperfused rat liver: Evidence for a role for Superoxide free radicals. Am J Physiol 1992; 262: G669-G676
33. 33. Ohashi I, Nishijima J, Murata A, et al: Inhibitory effect of a synthetic protease inhibitor (gabexate mesilate) on the respiratory burst oxidase in human neutrophils. J Biochem 1995; 118:1001-1006
34. 34. Novelli GP, Casali R, Bonizzoli M, et al: Antioxidant action of gabexate mesilate (FOY) in an experimental model of endotoxic shock. Minerva Anestesiol 1995; 61:509-513
35. 35. Ohno H, Kambayashi J, Chang SW, et al: FOY: [Ethyl p-(6-guanidinohexanoyloxy) benzoate] methanesulfonate as a serine proteinase inhibitor. II. In vivo effect on coagulo-fibrinolytic system in comparison with heparin or aprotinin. Thromb Res 1981; 24: 445-452
36. 2+ and intracellular acidification. Exp Hematol 1996; 24: 169-175
37. 37. Kushimoto S, Okajima K, Harada N: Role of microthrombus formation in ischemia/ reperfusion injury of rat liver. In: The Immune Consequences of Trauma, Shock and Sepsis: Mechanisms and Therapeutic Approaches. Faist E (Ed). Bologna, Italy, Monduzzi Editore, 1997, pp 495-502